Managing Ixabepilone Adverse Events with Dose Reduction

Clinical Breast Cancer

Volumn 13, Issue 1, 2013, Pages 1-6

  Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adverse event management; Dose reduction; Ixabepilone; Metastatic breast cancer; Peripheral neuropathy

Indexed keywords

CAPECITABINE; DOCETAXEL; ERIBULIN; IXABEPILONE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; REVIEW; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

EID: 84872321865     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.09.003     Document Type: Review

References (39)

1. F.Y. Lee, R. Borzilleri, C.R. Fairchild BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 2001 1429 1437 (Pubitemid 32708699)
2. J.J. Lee, S.M. Swain Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR) Semin Oncol 32 suppl 7 2005 S22 S26
3. P. Fumoleau, B. Coudert, N. Isambert Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues Ann Oncol 18 suppl 5 2007 v9 v15
4. F.Y. Lee, R. Borzilleri, C.R. Fairchild Preclinical discovery of ixabepilone, a highly active antineoplastic agent Cancer Chemother Pharmacol 63 2008 157 166
5. C. Dumontet, M.A. Jordan, F.F. Lee Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies Mol Cancer Ther 8 2009 17 25
6. E.S. Thomas, H.L. Gomez, R.K. Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 2007 5210 5217 (Pubitemid 350232252)
7. E.A. Perez, G. Lerzo, X. Pivot Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414 (Pubitemid 47310876)
8. J.A. Sparano, E. Vrdoljak, O. Rixe Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 2010 3256 3263
9. G.N. Hortobagyi, H.L. Gomez, R.K. Li Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes Breast Cancer Res Treat 122 2010 409 418
10. ® (ixabepilone) injection [prescribing information] 2010 Bristol-Myers Squibb Company Princeton NJ http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/022065s001lbl.pdf Accessed: May 23, 2012
11. J. Cortes, J. O'Shaughnessy, D. Loesch Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study Lancet 377 2011 914 923
12. D.A. Yardley, J.D. Hainsworth, W.N. Harwin TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial J Clin Oncol 29 suppl 2011 abstract:1103 www.asco.org Accessed: September 29, 2012
13. E.A. Perez, X. Pivot, E. Vrdoljak A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer Cancer Res 69 suppl 2009 abstract:6140
14. E. Thomas, J. Tabernero, M. Fornier Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 2007 3399 3406 (Pubitemid 47310875)
15. H. Roché, L. Yelle, F. Cognetti Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 2007 3415 3420 (Pubitemid 47310877)
16. J.A. Low, S.B. Wedam, J.J. Lee Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer J Clin Oncol 23 2005 2726 2734 (Pubitemid 46179462)
17. N. Denduluri, J.A. Low, J.J. Lee Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 2007 3421 3427 (Pubitemid 47310878)
18. E.B. Kossoff, N. Ngamphaiboon, T.J. Laudico Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients Med Oncol 28 suppl 1 2011 S115 S120
19. S. Moulder, H. Li, M. Wang A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group trial Breast Cancer Res Treat 119 2010 663 671
20. J.W. Smith, S.J. Vukelja, A.C. Rabe Final results of a phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer Poster presentation at American Society of Clinical Oncology 2010 Breast Cancer Symposium. Abstract 268 www.asco.org Accessed: September 29, 2012
21. V. Valero, L.D. Bosserman, D.A. Yardley Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048) J Clin Oncol 28 suppl 2010 abstract:1051 www.asco.org Accessed: September 29, 2012
22. Y.S. Yap, A. Kendall, G. Walsh Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer - how low can you go? Breast 16 2007 420 424 (Pubitemid 47109200)
23. T. Taguchi, T. Nakayama, N. Masuda Kinki Breast Cancer Study Group Study of low-dose capecitabine monotherapy for metastatic breast cancer Chemotherapy 56 2010 166 170
24. A.A. Kotsori, J.L. Noble, S. Ashley Moderate dose capecitabine in older patients with metastatic breast cancer: A standard option for first line treatment? Breast 19 2010 377 381
25. V. Michalaki, S. Gennatas, K. Gennatas Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results Anticancer Drugs 20 2009 204 207
26. D. Rossi, P. Alessandroni, V. Catalano Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer Clin Breast Cancer 7 2007 857 860
27. T. Osako, Y. Ito, S. Takahashi Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer Tumori 93 2007 129 132 (Pubitemid 46866701)
28. C. Sezgin, E. Kurt, T. Evrensel Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome South Med J 100 2007 27 32 (Pubitemid 46104929)
29. L. El-Helw, R.E. Coleman Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer Breast 14 2005 368 374 (Pubitemid 41510193)
30. B.T. Hennessy, A.M. Gauthier, L.B. Michaud Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 16 2005 1289 1296 (Pubitemid 41158473)
31. V. Harvey, H. Mouridsen, V. Semiglazov Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer J Clin Oncol 24 2006 4963 4970 (Pubitemid 46631397)
32. J. Stemmler, W. Mair, M. Stauch High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer Oncology 68 2005 71 78 (Pubitemid 40675012)
33. C. Massacesi, F. Marcucci, T. Boccetti Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer J Exp Clin Cancer Res 24 2005 43 48 (Pubitemid 40655861)
34. O. Silva, G. Lopes, D. Morgenzstern A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer Clin Breast Cancer 8 2008 162 167 (Pubitemid 351655931)
35. ® (paclitaxel) injection [prescribing information] 2010 Bristol-Myers Squibb Company Princeton, NJ http://packageinserts.bms.com/ pi/pi-taxol.pdf Accessed: September 29, 2012
36. J.M. Nabholtz, K. Gelmon, M. Bontenbal Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14 1996 1858 1867 (Pubitemid 26185461)
37. E.P. Winer, D.A. Berry, S. Woolf Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342 J Clin Oncol 22 2004 2061 2068 (Pubitemid 41095138)
38. A.D. Seidman, D. Berry, C. Cirrincione Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 2008 1642 1649
39. ® (capecitabine) [prescribing information] 2011 Genentech Inc. San Francisco http://www.gene.com/gene/products/information/ xeloda/pdf/pi.pdf Accessed: May 23, 2012